Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Conditions
Interventions
INCB000928
ruxolitinib
Locations
34
United States
City of Hope National Medical Center
Duarte, California, United States
City of Hope Orange County
Irvine, California, United States
Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
Stanford Cancer Center
Palo Alto, California, United States
Prebys Cancer Center
San Diego, California, United States
Emory University - Winship Cancer Institute
Atlanta, Georgia, United States
Start Date
March 19, 2021
Primary Completion Date
April 1, 2025
Completion Date
November 26, 2027
Last Updated
December 23, 2025
NCT03050268
NCT07357727
NCT07039422
NCT06976918
NCT06343805
NCT05012111
Lead Sponsor
Incyte Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions